- Pursuant to section 24 of the Veterans’ Support Act 2014, the Minister for Veterans gives notice of the amendment of 124 Statements of Principles under the Veterans’ Support Regulations 2014.
- The amendments take effect on the day after the publication of this notice.
- The amendments comprise a change to the definition of “cumulative equivalent dose” in clause 9, or in clause 1 of Schedule 1, as applicable in the Statements of Principles listed in paragraph 4 below. The new definition reads:
- “cumulative equivalent dose means the total dose of ionising radiation received by the particular organ or tissue from external exposure, internal exposure or both, apart from normal background radiation exposure in Australia, calculated in accordance with the methodology set out in Guide to calculation of ‘cumulative equivalent dose’ for the purpose of applying ionising radiation factors contained in Statements of Principles determined under Part XIA of the Veterans’ Entitlement Act 1986 (Cth), Australian Radiation Protection and Nuclear Safety Agency, as in force on 2 August 2017”.
- The amendments are compiled with the following Statements of Principles:
-
acoustic neuroma, 29/2011 & 30/2011
acquired cataract, 87/2016 & 88/2016
acute lymphoblastic leukaemia, 75/2012 & 76/2012
acute myeloid leukaemia, 71/2015 & 72/2015
adenocarcinoma of the kidney, 9/2013 & 10/2013
Alzheimer-type dementia, 22/2010 (Reasonable hypothesis version only)
angle-closure glaucoma, 25/2012 & 26/2012
aortic stenosis, 21/2013 & 22/2013
atherosclerotic peripheral vascular disease, 23/2012 & 24/2012
benign neoplasm of the eye and adnexa, 41/2016 & 42/2016
cardiomyopathy, 85/2015 & 86/2015
carotid arterial disease, 37/2012 & 38/2012
cerebral meningioma, 19/2009 & 20/2009
cerebrovascular accident, 65/2015 & 66/2015
chronic gastritis and chronic gastropathy, 25/2013 & 26/2013
chronic myeloid leukaemia, 47/2014 & 48/2014
chronic pancreatitis, 104/2011 & 105/2011
cirrhosis of the liver, 1/2017 (Reasonable hypothesis version only)
erectile dysfunction, 43/2013 & 44/2013
external burn, 110/2015 & 111/2015
fibrosing interstitial lung disease, 53/2013 & 54/2013
gastric ulcer and duodenal ulcer, 61/2015 & 62/2015
goitre, 23/2013 & 24/2013
Graves’ disease, 33/2013 & 34/2013
Hashimoto’s thyroiditis, 31/2013 & 32/2013
heart block, 1/2014 & 2/2014
hypothyroidism, 29/2013 & 30/2013
ischaemic heart disease, 1/2016 & 2/2016
malignant neoplasm of the bile duct, 69/2015 & 70/2015
malignant neoplasm of the bladder, 96/2011 & 97/2011
malignant neoplasm of the bone and articular cartilage, 106/2011 & 107/2011
malignant neoplasm of the brain, 85/2016 & 86/2016
malignant neoplasm of the breast, 96/2014 & 97/2014
malignant neoplasm of the cerebral meninges, 21/2009 & 22/2009
malignant neoplasm of the colorectum, 37/2013 & 38/2013
malignant neoplasm of the endometrium, 11/2016 & 12/2016
malignant neoplasm of the gallbladder, 89/2015 & 90/2015
malignant neoplasm of the liver, 21/2011 & 22/2011
malignant neoplasm of the lung, 92/2014 & 93/2014
malignant neoplasm of the oesophagus, 120/2015 & 121/2015
malignant neoplasm of the ovary, 70/2009 & 71/2009
malignant neoplasm of the renal pelvis and ureter, 98/2011 & 99/2011
malignant neoplasm of the salivary gland, 57/2015 & 58/2015
malignant neoplasm of the stomach, 58/2014 & 59/2014
malignant neoplasm of the thyroid gland, 39/2014 & 40/2014
malignant neoplasm of unknown primary site, 80/2014 & 81/2014
mesothelioma, 104/2015 & 105/2015
multiple sclerosis, 100/2011 (Reasonable hypothesis version only)
myelodysplastic syndrome, 73/2015 & 74/2015
myeloma, 69/2012 (Reasonable hypothesis version only)
narcolepsy, 7/2014 & 8/2014
neoplasm of the pituitary gland, 53/2015 (Reasonable hypothesis version only)
non-aneurysmal aortic atherosclerotic disease, 15/2012 & 16/2012
Non-Hodgkin’s lymphoma, 28/2010 (Reasonable hypothesis version only)
non-melanotic malignant neoplasm of the skin, 7/2016 & 8/2016
open-angle glaucoma, 27/2012 & 28/2012
optochiasmatic arachnoiditis, 57/2016 & 58/2016
osteomyelitis, 90/2014 & 91/2014
otitis externa, 58/2012 & 59/2012
otitis media, 51/2014 & 52/2014
peritoneal adhesions, 3/2016 & 4/2016
renal artery atherosclerotic disease, 102/2011 & 103/2011
soft tissue sarcoma, 5/2015 & 6/2015
tinnitus, 33/2012 & 34/2012
trigeminal neuropathy, 79/2015 & 80/2015
- These amended Statements of Principles are available on the website of the Australian Government Repatriation Medical Authority: www.rma.gov.au.
Dated at Wellington this 29th day of November 2017.
Hon RON MARK, Minister for Veterans.